Wolfe Research Bullish on Roivant Sciences: Outperform Rating

Wolfe Research Initiates Coverage on Roivant Sciences with Outperform Rating

Biopharmaceutical sector expert, Wolfe Research, has commenced its analysis of Roivant Sciences, assigning the company an Outperform rating with an ambitious price target of $17.00. This bold move by Wolfe Research underscores a strong confidence in Roivant Sciences, a firm distinguished by its impressive cash reserves and a strategic approach to debt management.